PBM Rebating Practices: How Much Do Employer Plan Sponsors Really Know?

 
• By Cathy Kelly
  
Generate a summary of this article
Listen to this article
Beta

A National Pharmaceutical Council survey of self-insured employers offers a new perspective on pharmacy benefit manager claims that rebating practices only reflect the decisions made by their clients.

Employers May Need To Rethink Their Approach To PBM Contracting. (Shutterstock)

Nearly two-thirds (62.7%) of employers with self-funded pharmacy benefits reported agreements for specialty drugs that include a guaranteed total rebate amount over the course of a contract, according to a nationalsurveyby National Pharmaceutical Council researchers.

Key Takeaways

  • Almost 63% of employers offering self-insured pharmacy benefits choose guaranteed rebates in their vendor contracts with PBMs, according to a survey by the National Pharmaceutical Council.

Not surprisingly, employers with rebate guarantees “ascribed a higher level of importance” to guarantees in the PBM bidding process than...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Pink Sheet

Pink Sheet Podcast: Understanding the US FDA’s CDER Leadership - Clone

 
• By Mary Jo Laffler

Pink Sheet reporter and editors discuss the likely impacts of Center for Drug Evaluation and Research Director Richard Pazdur’s retirement from the FDA and Tracy Beth Høeg becoming the center’s acting director.

Test FDA Voucher Program Approvals Will Come From Product Centers, But Ambiguity Lingers - Clone

 
• By Sue Sutter

Approval decisions for the FDA's CNPV pilot program will be made by product center officials, but it's unclear if the responsibility lies with center directors or review office leaders.

Pink Sheet Podcast: Understanding the US FDA’s CDER Leadership

 
• By Mary Jo Laffler

Pink Sheet reporter and editors discuss the likely impacts of Center for Drug Evaluation and Research Director Richard Pazdur’s retirement from the FDA and Tracy Beth Høeg becoming the center’s acting director.

Test FDA Voucher Program Approvals Will Come From Product Centers, But Ambiguity Lingers

 
• By Sue Sutter

It is unclear in a revised staff manual guide whether Commissioner's National Priority Voucher program approval “recommendations” from the drug and biologic center directors will be advisory or decisional, experts told the Pink Sheet.

More from Medtech Insight

Test Focus Of Tariff Conversations Shifts To Stability, AdvaMed Says - Clone

 
• By Elizabeth Orr

AdvaMed president Scott Whitaker said the group is focused on the need for tariff stability in conversations with the Trump administration. The organization remains optimistic about other policy areas. New chairman and ResMed CEO Mick Farrell laid out his five priorities.

US Original PMAs and Panel-Track Supplementss

 
• By Olga Zviezdicheva, Reed Miller, and Nabil

Class III devices and panel-track supplements approved by US FDA’s Center for Devices and Radiological Health. Data derived from FDA.gov. Updated weekly.

Test Focus Of Tariff Conversations Shifts To Stability, AdvaMed Says

 
• By Elizabeth Orr

AdvaMed president Scott Whitaker said the group is focused on the need for tariff stability in conversations with the Trump administration. The organization remains optimistic about other policy areas. New chairman and ResMed CEO Mick Farrell laid out his five priorities.